BioCentury
ARTICLE | Clinical News

Gleevec regulatory update

May 26, 2003 7:00 AM UTC

The FDA granted marketing approval for Gleevec to treat pediatric patients with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia (CML) whose disease has recurred after ste...